“…In recent years, there has been an increasing interest in the gut microbiota as a potential target for novel therapeutics, due to its tremendous impact on the brain, behavior, and health ( Cryan et al., 2019 ). While the majority of work concerning the role of the gut microbiota in neuropsychiatric conditions has focused on autism spectrum disorder ( Sharon et al., 2019 ; Wang et al., 2019 ), Alzheimer’s disease ( Vogt et al., 2017 ; Bulgart et al., 2020 ), Parkinson’s disease ( Petrov et al., 2017 ; Aho et al., 2019 ), depression ( Bastiaanssen et al., 2020 ; Yang et al., 2020 ), anxiety ( Jiang et al., 2018 ) and schizophrenia ( Zhu et al., 2019 ; Golofast and Vales, 2020 ), the evidence of interactions between the gut microbiota and substance use has been relatively limited ( Qin et al., 2021 ; Salavrakos et al., 2021 ), and even less is known in the context of METH use.…”